… This potentially puts the preterm neonates at risk of receiving sub-… disposition and metabolism
in preterm neonates. We highlight … Midazolam is metabolized by CYP3A4 at a slower rate …

… of pharmacokinetic (PK), pharmacodynamic (PD), and safety … V d tends to be underpredicted
in preterm neonates; most … measurements of the V d of midazolam, it is known that V d is …

… in preterm infants as follows: 4 µmol/L for a preterm infant: 158 … from another study using
midazolam as the CYP3A probe … sildenafil iv Furthermore, oral absorption in preterm infants is …

… than 14 days, clonidine may facilitate weaning or transition from intravenous to oral therapy.
… Furthermore, there is a lack of pharmacokinetic data on DEX in preterm infants; therefore, …

… in vulnerable populations like preterm neonates. Although … occurs via inhalational or
intravenous routes, and other drug … clearance of levobupivacaine and midazolam and CYP1A2 for …

… for midazolam, alfentanil, caffeine, ibuprofen, gentamicin and vancomycin in preterm neonates
… Studies include single oral and intravenous (IV) doses of APAP as indicated and can be …

… drug pharmacokinetics and pharmacodynamics. Furthermore, … in term infants appears to be
different from preterm infants and … premature infants associated with midazolam intravenous …

… nervous system protected the newborn, especially the preterm infant, from experiencing pain.
In … and metabolism of intravenous midazolam in preterm infants. Clinical Pharmacology & …

… Morphine pharmacodynamics in mechanically ventilated preterm neonates undergoing …
The aim of the study was to investigate the pharmacokinetics of midazolam, after intravenous …

… sildenafil in premature infants following both intravenous and … PK in 2 cohorts of premature
infants; the first group was … received a single dose of intravenous (IV) sildenafil for the purpose …